WO2000006185A3 - Methods of using lanreotide, a somatostatin analogue - Google Patents

Methods of using lanreotide, a somatostatin analogue Download PDF

Info

Publication number
WO2000006185A3
WO2000006185A3 PCT/US1999/017294 US9917294W WO0006185A3 WO 2000006185 A3 WO2000006185 A3 WO 2000006185A3 US 9917294 W US9917294 W US 9917294W WO 0006185 A3 WO0006185 A3 WO 0006185A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
diseases
cys
lanreotide
methods
Prior art date
Application number
PCT/US1999/017294
Other languages
French (fr)
Other versions
WO2000006185A2 (en
Inventor
Jacques-Pierre Moreau
Original Assignee
Biomeasure Inc
Moreau Jacques Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002335654A priority Critical patent/CA2335654A1/en
Priority to MXPA01000969A priority patent/MXPA01000969A/en
Application filed by Biomeasure Inc, Moreau Jacques Pierre filed Critical Biomeasure Inc
Priority to BR9912609-5A priority patent/BR9912609A/en
Priority to KR1020017001277A priority patent/KR20010071071A/en
Priority to EP99937658A priority patent/EP1100532A2/en
Priority to PL99346361A priority patent/PL346361A1/en
Priority to IL14083799A priority patent/IL140837A0/en
Priority to JP2000562039A priority patent/JP2002521456A/en
Priority to HU0102839A priority patent/HUP0102839A3/en
Priority to AU52447/99A priority patent/AU770193B2/en
Priority to NZ509348A priority patent/NZ509348A/en
Publication of WO2000006185A2 publication Critical patent/WO2000006185A2/en
Publication of WO2000006185A3 publication Critical patent/WO2000006185A3/en
Priority to NO20010481A priority patent/NO324123B1/en
Priority to AU2004201783A priority patent/AU2004201783A1/en
Priority to IL181349A priority patent/IL181349A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-g(b)-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, where the Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, endocronological diseases and/or conditions, various types of cancers and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.
PCT/US1999/017294 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue WO2000006185A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
HU0102839A HUP0102839A3 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof
JP2000562039A JP2002521456A (en) 1998-07-30 1999-07-29 How to use somatostatin analogs
BR9912609-5A BR9912609A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analog
MXPA01000969A MXPA01000969A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue.
EP99937658A EP1100532A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue
PL99346361A PL346361A1 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
AU52447/99A AU770193B2 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
CA002335654A CA2335654A1 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
KR1020017001277A KR20010071071A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
IL14083799A IL140837A0 (en) 1998-07-30 1999-07-29 Method of using lanreotide, a somatostatin analogue
NZ509348A NZ509348A (en) 1998-07-30 1999-07-29 Use of a somatostatin analogue Lanreotide
NO20010481A NO324123B1 (en) 1998-07-30 2001-01-29 Use of lanreotide, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition
AU2004201783A AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue
IL181349A IL181349A0 (en) 1998-07-30 2007-02-15 Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9469398P 1998-07-30 1998-07-30
US12652598A 1998-07-30 1998-07-30
US60/094,693 1998-07-30
US09/126,525 1998-07-30

Publications (2)

Publication Number Publication Date
WO2000006185A2 WO2000006185A2 (en) 2000-02-10
WO2000006185A3 true WO2000006185A3 (en) 2000-08-03

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017294 WO2000006185A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue

Country Status (16)

Country Link
EP (1) EP1100532A2 (en)
JP (1) JP2002521456A (en)
KR (1) KR20010071071A (en)
CN (1) CN1334742A (en)
AR (1) AR023633A1 (en)
AU (2) AU770193B2 (en)
BR (1) BR9912609A (en)
CA (1) CA2335654A1 (en)
CZ (1) CZ2001157A3 (en)
HU (1) HUP0102839A3 (en)
IL (2) IL140837A0 (en)
MX (1) MXPA01000969A (en)
NO (1) NO324123B1 (en)
NZ (1) NZ509348A (en)
PL (1) PL346361A1 (en)
WO (1) WO2000006185A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
ES2284859T3 (en) 2001-03-06 2007-11-16 Il Consorzio Ferrara Richerche PROCEDURE TO MODULATE THE PROLIFERATION OF THYROID MEDULAR CARCINOMA CELLS.
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
US20110034381A1 (en) 2002-01-22 2011-02-10 David Kleinberg Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
ES2614990T3 (en) 2008-06-12 2017-06-02 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (en) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 Landscape plant growth retardant and preparation method thereof
WO2013153129A1 (en) * 2012-04-12 2013-10-17 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
CN105168115A (en) * 2015-09-02 2015-12-23 中国药科大学 Oral medication path of somatostatin analogue polypeptide drug
WO2017212390A1 (en) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Process for lanreotide acetate preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
WO1998008529A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
WO1998051332A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
WO1998008529A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
WO1998051332A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ANTHONY L B ET AL: "Case report: lanreotide in the management of hypercalcemia of malignancy.", AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol. 309, no. 6, June 1995 (1995-06-01), pages 312 - 314, XP000867465 *
BARTLETT D L ET AL: "Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia.", SURGERY (ST LOUIS), vol. 118, no. 1, July 1995 (1995-07-01), pages 87 - 97, XP000907234 *
CHANSON P: "Traitements médicamenteux des adénomes hypophysaires.", REVUE DU PRATICIEN, vol. 46, 15 June 1996 (1996-06-15), pages 1509 - 1513, XP000907252 *
HASLER W ET AL: "ROLE OF THE PYLORUS IN THE PREVENTION OF DUODENO-GASTRIC REFLUX EFFECTS OF THE SOMATOSTATIN ANALOG.", GASTROENTEROLOGY, vol. 100, no. 5, 19 May 1991 (1991-05-19) - 22 May 1991 (1991-05-22), pages A448, XP000866191 *
HOELDTKE R D ET AL: "Treatment of orthostatic hypotension with midodrine and octreotide.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 83, no. 2, February 1998 (1998-02-01), pages 339 - 343, XP000907222 *
JAFFRAIN-REA ML ET AL: "Visual improvement during octreotide therapy in a case of episellar meningioma.", CLINICAL NEUROLOGY AND NEUROSURGERY, vol. 100, no. 1, March 1998 (1998-03-01), pages 40 - 43, XP000907228 *
KANG S & MISHKIN F S: "Visualization of Paget's disease during somatostatin receptor scintigraphy.", CLINICAL NUCLEAR MEDICINE, vol. 24, no. 11, November 1999 (1999-11-01), pages 900 - 902, XP000907230 *
KHOO D ET AL: "Palliation of malignant intestinal obstruction using octreotide", EUROPEAN JOURNAL OF CANCER, vol. 30A, no. 1, 1994, pages 28 - 30, XP000866064 *
KIRK J M W ET AL: "Somatostatin analogue in short term management of hyperinsulinism", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 63, no. 12, 1988, pages 1493-1494, XP002053035 *
LAMRANI A ET AL: "Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 43, no. 1, January 1997 (1997-01-01), pages 65 - 70, XP000870053 *
MOSDELL K W ET AL: "Emerging indications for octreotide therapy, Part 1.", AMERICAN JOURNAL OF HOSPITAL PHARMACY, vol. 51, no. 9, 1 May 1994 (1994-05-01), pages 1184 - 1192, XP000866264 *
MOTTET C ET AL: "Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.", HEPATOLOGY, vol. 27, no. 4, April 1998 (1998-04-01), pages 920 - 925, XP000870061 *
ONO, MASASHI ET AL: "Effects of octreotide acetate treatment for scleroderma bowel.", KAWASAKI MEDICAL JOURNAL, vol. 22, no. 4, 1996, pages 233 - 237, XP000866213 *
PAVLOVIC M. ET AL: "Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide.", ARCHIVES OF DERMATOLOGY, vol. 131, no. 10, October 1995 (1995-10-01), pages 1207-1209, XP000866063 *
RIEU M ET AL: "Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma.", HORMONE RESEARCH, vol. 39, no. 5-6, November 1993 (1993-11-01), pages 207 - 212, XP000907231 *
SOBHANI I ET AL: "Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 41, no. 2, February 1996 (1996-02-01), pages 109 - 114, XP000870052 *
SRKALOVIC G ET AL: "EVALUATION OF RECEPTORS FOR SOMATOSTATIN IN VARIOUS TUMORS USING DIFFERENT ANALOGS", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 70, no. 3, March 1990 (1990-03-01), pages 661 - 669, XP000907224 *
WECKBECKER G ET AL: "SOMATOSTATIN ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER", PHARMACOLOGY AND THERAPEUTICS, vol. 60, no. 2, 1994, pages 245 - 264, XP002072560 *
WOLTERING E A ET AL: "DETECTION OF OCCULT GASTRINOMAS WITH IODINE 125-LABELED LANREOTIDE AND INTRAOPERATIVE GAMMA-DETECTION", SURGERY, vol. 116, no. 6, December 1994 (1994-12-01), pages 1139 - 1147, XP000866097 *
ZEILKE A ET AL: "Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial.", SURGERY (ST LOUIS), vol. 121, no. 6, June 1997 (1997-06-01), pages 606 - 610, XP000907227 *

Also Published As

Publication number Publication date
EP1100532A2 (en) 2001-05-23
AU770193B2 (en) 2004-02-12
NO324123B1 (en) 2007-08-27
CZ2001157A3 (en) 2002-02-13
HUP0102839A3 (en) 2002-02-28
NO20010481L (en) 2001-03-21
AU5244799A (en) 2000-02-21
AR023633A1 (en) 2002-09-04
MXPA01000969A (en) 2003-04-07
KR20010071071A (en) 2001-07-28
IL181349A0 (en) 2007-07-04
IL140837A0 (en) 2002-02-10
NZ509348A (en) 2004-02-27
JP2002521456A (en) 2002-07-16
AU2004201783A1 (en) 2004-05-27
NO20010481D0 (en) 2001-01-29
CA2335654A1 (en) 2000-02-10
CN1334742A (en) 2002-02-06
BR9912609A (en) 2001-05-02
WO2000006185A2 (en) 2000-02-10
HUP0102839A2 (en) 2002-01-28
PL346361A1 (en) 2002-02-11

Similar Documents

Publication Publication Date Title
WO2000006185A3 (en) Methods of using lanreotide, a somatostatin analogue
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
LU91928I2 (en) Ipilimumab and its pharmaceutically acceptable derivatives (YERVOY®)
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
WO2003079979A3 (en) Method for treating congestive heart failure
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO1999004772A3 (en) Use of levobupivacaine
WO2003034996A3 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
WO2004020668A3 (en) Method for treating synovial sarcoma
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
WO2003045942A3 (en) Chemokine receptor antagonists and methods of use thereof
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2001009119A3 (en) Chemokine receptor antagonists
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003020221A3 (en) Method of treating cancerous disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808953.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 140837

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-157

Country of ref document: CZ

Ref document number: 1999937658

Country of ref document: EP

Ref document number: 509348

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 52447/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2335654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000969

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 562039

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/00793

Country of ref document: ZA

Ref document number: 200100793

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999937658

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744846

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-157

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999937658

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001277

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 52447/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181349

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: PV2001-157

Country of ref document: CZ